Cargando…
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety. Objectives: Our study aims to evaluate the minimum plasma...
Autores principales: | Lu, Jiayue, Cai, Hong, Hao, Yujun, Lin, Zhang, Liu, Shang, Zhan, Yaping, Ding, Li, Huang, Meilan, Li, Zhenyuan, Xu, Lan, Yan, Xiujuan, Yang, Li, Zhang, He, Zhang, Wei, Zhao, Li, Zhao, Junli, Wang, Ting, Gu, Leyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213535/ https://www.ncbi.nlm.nih.gov/pubmed/37251313 http://dx.doi.org/10.3389/fphar.2023.1161897 |
Ejemplares similares
-
Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
por: Yan, Jiayi, et al.
Publicado: (2023) -
483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023) -
Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
por: Zhang, Ai-hua, et al.
Publicado: (2023) -
Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
por: Xiong, Yu, et al.
Publicado: (2023) -
Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
por: Wei, An-Hua, et al.
Publicado: (2023)